# ROsuvastatin Pretreatment to Reduce MyocArdial Periprocedural Necrosis:Comparison With Atorvastatin Reloading

Study · id `cardio:ct-nct01228227` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01228227](<https://clinicaltrials.gov/study/NCT01228227>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01228227

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It plans to enroll 310 participants.

## Technical summary

Registry record NCT01228227. Randomized; no masking; primary purpose treatment. Start 2010-10 (registry gives no type); primary completion 2011-04 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 310 participants (planned count; ClinicalTrials.gov record NCT01228227, source copy `cardio:ctgov-nct01228227-2013-01-04`, retrieved 2026-10-26)
- Start date: 2010-10 (registry gives no type) (ClinicalTrials.gov record NCT01228227, source copy `cardio:ctgov-nct01228227-2013-01-04`, retrieved 2026-10-26)
- Primary completion: 2011-04 (actual) (ClinicalTrials.gov record NCT01228227, source copy `cardio:ctgov-nct01228227-2013-01-04`, retrieved 2026-10-26)
- Completion: 2011-08 (actual) (ClinicalTrials.gov record NCT01228227, source copy `cardio:ctgov-nct01228227-2013-01-04`, retrieved 2026-10-26)
- Countries: Italy (ClinicalTrials.gov record NCT01228227, source copy `cardio:ctgov-nct01228227-2013-01-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01228227-2013-01-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: ROsuvastatin Pretreatment to Reduce MyocArdial Periprocedural Necrosis:Comparison With Atorvastatin Reloading
- Acronym: ROMAIIReload
- Condition: Assess the Periprocedural Myocardial Necrosis
- Intervention (Drug): ATORVASTATIN 80 mg
- Intervention (Drug): ROSUVASTATIN 40 mg
- Lead sponsor: Gennaro Sardella
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry intervention is a member of this class by a sourced record link: Statins (`cardio:statins`)

## Provenance

Content hash: 3a10ba5a3baa85f9e0002a7b54f26ed29777dac6ff264af12f5f91e5e7e3e596
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
